This observation led the authors to propose a cardioprotective role for the NLRP3 inflammasome in myocardial IRI, concluding that targeting NLRP3 or ASC may not be beneficial in the context of acute myocardial infarction and revascularization therapy [144]. Here, NLRP3 is linked to myocardial infarction.